MissionIR Articles

Today before the opening bell, Cardium Therapeutics announced the publication of preclinical findings demonstrating that cardiac ischemia is an important part of adenovector gene delivery (transfection) in mammalian hearts. The new findings were published in…

I’m not new to the world of energy supplements. I’m constantly trying to maximize the limited number of waking hours to get as much done as possible. Often I end up pushing myself too hard…

“Relax.” This advice, something I regularly hear from my family and friends, is so often easier said than done. Work, gym, bills, appointments, friends, family…we all deal with these responsibilities, and life certainly doesn’t slow…

Cardium Therapeutics was a focus ticker of an article published over the weekend at the premier website for actionable stock market opinion and analysis, Seeking Alpha. Seeking Alpha handpicks articles from the world’s top market…

In a just published article in San Diego Biotechnology Connection, Cardium Therapeutics was highlighted for its work in developing Generx, a DNA-based angiogenic growth factor therapeutic for the potential treatment of patients with advanced coronary…

Cardium Therapeutics is a small biotech company focused on the acquisition and strategic development of new and innovative bio medical opportunities that have the potential to address unmet medical needs. Since Cardium was initially funded…

Cardium Therapeutics, a California-based health sciences and regenerative medicine company, is focused on the acquisition and development of innovative new bio-medical products and businesses with the potential to address significant unmet medical needs, as well…

Cardium Therapeutics utilizes a growth strategy based on acquisition of businesses with the potential to address unmet medical needs. The company’s investment portfolio includes the Tissue Repair Company; Cardium Biologics, medical technology companies primarily focused…

Today before the opening bell, Cardium Therapeutics announced that it will be launching its new MedPodium Neo-Chill Nutra-App® at the National Association of Chain Drug Stores (NACDS) Marketplace 2012. MedPodium’s Neo-Chill Nutra-App® contains 200 mg…

Cardium Therapeutics announced that its Chairman and CEO, Christopher J. Reinhard, will be one of the presenters at the Marcum MicroCap Conference on June 20, 2012, at 11:00 a.m. Eastern Time. A live audio webcast…

Earlier this morning, Cardium Therapeutics announced that it has signed an agreement with Advanced Biosciences Research, an affiliate of bioRASI, for the planned commercialization of Cardium’s professional-use Excellagen® topical wound care management product in Russia…

MissionIR will be assisting Cardium Therapeutics in the implementation of a strategic digital and social media investor relations campaign. Through a network of investor-oriented sites and a full suite of investor awareness services, MissionIR develops…

Cardium Therapeutics is a health sciences and regenerative medicine company focused on acquiring and strategically developing new and innovative products and businesses to address significant unmet medical needs. Comprised of large-market opportunities with definable pathways…

Cardium Therapeutics, a San Diego based health sciences and regenerative medicine company, and its subsidiary, Tissue Repair Company, have contracted the Burlington, Massachusetts, site of Albany Molecular Research (AMRI) to manufacture sterile pre-filled syringes, in…

AMRI announced today that its Burlington site was contracted by Cardium Therapeutics and its subsidiary, Tissue Repair Company (“Cardium”) to manufacture sterile pre-filled syringes in support of the U.S. introduction of Excellagen®, a professional-use, formulated…

Cardium Therapeutics today announced that Christopher J. Reinhard, Chairman & CEO will present a corporate overview and participate in a Regenerative Medicine Panel being held at the Sachs 2012 Science, Partner, and Investment Forum: Gateway…

Cardium Therapeutics today announced a late-breaking poster presentation at the American Society of Gene & Cell Therapy (ASGCT) 15th Annual Meeting being held May 16-19, 2012 at the Pennsylvania Convention Center in Philadelphia, PA. (Photo:…

Cardium Therapeutics today announced an agreement with UK-based Angel Biomedical Limited, a subsidiary of Angel Biotechnology Holdings plc (AIM: ABH), a global biopharmaceutical contract manufacturer, covering the manufacture of formulated collagen for Cardium’s Excellagen® product,…

Cardium Therapeutics today presented its financial results for the first quarter ended March 31, 2012, and other recent developments. (Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO) In addition to the announcement of first quarter 2012 financial results, Cardium reported its…